Uppsala University Hospital

Sana Biotechnology Reports Breakthrough in Type 1 Diabetes Cell Therapy with 6-Month Clinical Data

- Sana Biotechnology presented positive 6-month clinical results showing hypoimmune-modified pancreatic islet cells survived and functioned without immunosuppression in type 1 diabetes patients. - The New England Journal of Medicine published the company's 12-week clinical results, demonstrating stable C-peptide production and successful immune evasion. - The company raised $105 million in new capital and expects to file investigational new drug applications for SC451 and SG299 as early as 2026. - Clinical data from ongoing GLEAM and VIVID trials evaluating allogeneic CAR T cell therapies are expected to be reported in 2025.